The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
XEN-D0501, a Novel Transient Receptor Potential Vanilloid 1 Antagonist, Does Not Reduce Cough in Patients with Refractory Cough
Open accessAbstract
RATIONALE: Heightened cough responses to inhaled capsaicin, a transient receptor potential vanilloid 1 (TRPV1) agonist, are characteristic of patients with chronic cough. However, previously, a TRPV1 antagonist (SB-705498) failed to improve spontaneous cough frequency in these patients, despite small reductions in capsaicin-evoked cough. OBJECTIVES: XEN-D0501 (a potent TRPV1 antagonist) was compared with SB-705498 in preclinical studies to establish whether an improved efficacy profile would support a further clinical trial of XEN-D0501 in refractory chronic cough. METHODS: XEN-D0501 and SB-705498 were profiled against capsaicin in a sensory nerve activation assay and in vivo potency established against capsaicin-induced cough in the guinea pig. Twenty patients with refractory chronic cough participated in a double-blind, randomized, placebo-controlled crossover study evaluating the effect of 14 days of XEN-D0501 (oral, 4 mg twice daily) versus placebo on awake cough frequency (primary outcome), capsaicin-evoked cough, and patient-reported outcomes. MEASUREMENTS AND MAIN RESULTS: XEN-D0501 was more efficacious and 1,000-fold more potent than SB-705498 at inhibiting capsaicin-induced depolarization of guinea pig and human isolated vagus nerve. In vivo XEN-D0501 completely inhibited capsaicin-induced cough, whereas 100 times more SB-705498 was required to achieve the same effect. In patients, XEN-D0501 substantially reduced maximal cough responses to capsaicin (mean change from baseline, XEN-D0501, -19.3 ± 16.4) coughs; placebo, -1.8 ± 5.8 coughs; P < 0.0001), but not spontaneous awake cough frequency (mean change from baseline, XEN-D0501, 6.7 ± 16.9 coughs/h; placebo, 0.4 ± 13.7 coughs/h; P = 0.41). CONCLUSIONS: XEN-D0501 demonstrated superior efficacy and potency in preclinical and clinical capsaicin challenge studies; despite this improved pharmacodynamic profile, spontaneous cough frequency did not improve, ruling out TRPV1 as an effective therapeutic target for refractory cough. Clinical trial registered with www.clinicaltrialsregister.eu (2014-000306-36).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72351 · Cited by 6,277
Cited by
ERS guidelines on the diagnosis and treatment of chronic cough in adults and children
Morice, A. H., Millqvist, E., Bieksiene, K., Birring, S. S., Dicpinigaitis, P., Domingo Ribas, C., Hilton Boon, M., Kantar, A., Lai, K., McGarvey, L., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.01136-2019 · Cited by 893
Self-citationAdvances in TRP channel drug discovery: from target validation to clinical studies
Koivisto, A.-P., Belvisi, M. G., Gaudet, R., & Szallasi, A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00268-4 · Cited by 537
Self-citationZhang, M., Ma, Y., Ye, X., Zhang, N., Pan, L., & Wang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01464-x · Cited by 522
Song, W.-J., Hui, C. K. M., Hull, J. H., Birring, S. S., McGarvey, L., Mazzone, S. B., & Chung, K. F. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00125-9 · Cited by 372
Self-citationCough hypersensitivity and chronic cough
Chung, K. F., McGarvey, L., Song, W.-J., Chang, A. B., Lai, K., Canning, B. J., Birring, S. S., Smith, J. A., & Mazzone, S. B. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00370-w · Cited by 309
Self-citation
Metadata
- Authors
- Belvisi, M. G., Birrell, M. A., Wortley, M. A., Maher, S. A., Satia, I., Badri, H., Holt, K., Round, P., McGarvey, L., Ford, J., & Smith, J. A.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-11-15
- Volume
- 196
- Issue
- 10
- Pages
- 1255-1263
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2723324226
- Cited by
- 158
- References
- 1
- FWCI
- 12.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: XEN-D0501, a Novel Transient Receptor Potential Vanilloid 1 Antagonist, Does Not Reduce Cough in Patients with Refractory Cough. https://app.cochat.ai/papers/10.1164/rccm.201704-0769oc
- The paper
- Belvisi, M. G., Birrell, M. A., Wortley, M. A., Maher, S. A., Satia, I., Badri, H., Holt, K., Round, P., McGarvey, L., Ford, J., & Smith, J. A. (2017). XEN-D0501, a Novel Transient Receptor Potential Vanilloid 1 Antagonist, Does Not Reduce Cough in Patients with Refractory Cough. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201704-0769oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.